(Q38169241)

30 August 2017

Eosinophilic phenotypes of airway disease (English)

1 reference

30 August 2017

Ian D Pavord

1

0 references

publication date

1 December 2013

1 reference

Proceedings of the American Thoracic Society

30 August 2017

1 reference

30 August 2017

10 Suppl

1 reference

30 August 2017

S143-9

1 reference

Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity.

30 August 2017

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Eosinophilic bronchitis: clinical manifestations and implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Eosinophilic bronchitis is an important cause of chronic cough.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Non-eosinophilic cor ticosteroid unresponsive asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Mast-cell infiltration of airway smooth muscle in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Exhaled nitric oxide measurements: clinical application and interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Exhaled nitric oxide: a predictor of steroid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Use of exhaled nitric oxide measurements to guide treatment in chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Inflammometry to assess airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Dupilumab in persistent asthma with elevated eosinophil levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Induced Sputum Inflammatory Mediator Concentrations in Eosinophilic Bronchitis and Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

Prednisone-dependent asthma: inflammatory indices in induced sputum

21 January 2018

1 reference

https://api.crossref.org/works/10.1513%2FANNALSATS.201306-168AW

10.1513/ANNALSATS.201306-168AW

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24313765